Huntingtin (D7F7) XP® Rabbit mAb

For Research Use Only. Not for Use in Diagnostic Procedures.

**Applications:**
- WB, IP, IHC-P, IF-F

**Reactivity:**
- H M R

**Sensitivity:**
- Endogenous

**MW (kDa):**
- 350

**Source/Isotype:**
- Rabbit IgG

**UniProt ID:**
- #P42858

**Entrez-Gene Id:**
- 3064

**Product Usage Information**

<table>
<thead>
<tr>
<th>Application</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Western Blotting</td>
<td>1:1000</td>
</tr>
<tr>
<td>Immunoprecipitation</td>
<td>1:50</td>
</tr>
<tr>
<td>Immunohistochemistry (Paraffin)</td>
<td>1:400 - 1:1600</td>
</tr>
<tr>
<td>Immunofluorescence (Frozen)</td>
<td>1:50 - 1:200</td>
</tr>
</tbody>
</table>

**Storage**

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

For a carrier free (BSA and azide free) version of this product see product #31873.

**Specificity / Sensitivity**

Huntingtin (D7F7) XP® Rabbit mAb detects endogenous levels of total huntingtin protein. Species cross-reactivity for IHC-P is in rodent only.

**Source / Purification**

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro1218 of human huntingtin protein.

**Background**

Huntington’s Disease (HD) is a fatal neurodegenerative disorder characterized by psychiatric, cognitive, and motor dysfunction. Neuropathology of HD involves specific neuronal subpopulations: GABA-ergic neurons of the striatum and neurons within the cerebral cortex selectively degenerate (1,2). The genetic analysis of HD has been the flagship study of inherited neurological diseases from initial chromosomal localization to identification of the gene.

Huntingtin is a large (340-350 kD) cytosolic protein that may be involved in a number of cellular functions such as transcription, gastrulation, neurogenesis, neurotransmission, axonal transport, neural positioning, and apoptosis (2,3). The HD gene from unaffected individuals contains between 6 and 34 CAG trinucleotide repeats, with expansion beyond this range causing the onset of disease symptoms. A strong inverse correlation exists between the age of onset in patients and the number of huntingtin gene CAG repeats encoding a stretch of polyglutamine peptides (1,2). The huntingtin protein undergoes numerous post-translational modifications including phosphorylation, ubiquitination, sumoylation, palmitoylation, and cleavage (2). Phosphorylation of Ser421 by Akt can partially counteract the toxicity that results from the expanded polyglutamine tract. Varying Akt expression in the brain correlates with regional differences in huntingtin protein phosphorylation; this pattern inversely correlates with the regions that are most affected by degeneration in diseased brain (2). A key step in the disease is the proteolytic cleavage of huntingtin into amino-terminal fragments that contain expanded glutamine repeats and translocate into the nucleus. Caspase mediated cleavage of huntingtin at Asp513 is associated with increased polyglutamine aggregate formation and toxicity. Phosphorylation of Ser434 by CDK5 protects against cleavage (2,3).

**Background References**


**Species Reactivity**

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

**Western Blot Buffer**

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

**Applications Key**

- WB: Western Blotting
- IP: Immunoprecipitation
- IHC-P: Immunohistochemistry (Paraffin)
- IF-F: Immunofluorescence (Frozen)

**Cross-Reactivity Key**
Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer’s terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.